“Abstract: … A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol [i.e., Vitamin D3] booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (ORadj 0.13, 95% CI 0.05–0.35, p < 0.001). This finding was replicated in a validation cohort of 541 patients (ORadj 0.38, 95% CI 0.17–0.84, p = 0.018). In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19.”
All articles published by MDPI are made immediately available worldwide under an open access license. This means: everyone has free and unlimited access to the full-text of all articles published in MDPI journals; everyone is free to re-use the published material if proper accreditation/citation of the original publication is given; Source: https://www.mdpi.com/openaccess